

Disclosure statement

경희의대 소아청소년과
배종우
(의편협 출판윤리위 간사)

Disclosure statement의 번역

- 이해관계 선언 ?
- 이해관계 관련 선언 ?
- 미확정

예시를 봅시다

예 1: 학회 발표

- 제목: Manuscripts Preparation and the Process of Peer-Reviewed Publication
- 소속: The Editors of The Journal of Pediatrics
- 발표자: William F. Ballsteri, MD, Stephan R, Daniels, MD, PhD, Alan H, Jobs, MD, PhD, Sarah S, Long, MD, Thomas R, Welch, MD, Robert W. Wilmott, MD.
- 발표학회: 2009년 Pediatric Academic Societies 학회
(미국, 발티모어, 2009년 5월1일-5일)
- Disclosure Statements
Stephan R. Daniels, MD, PhD, Sarah S. Long, MD, Thomas R. Welch, MD, and Robert W. Wilmott, MD, have no relevant financial relationships to disclose or conflicts of interest to resolve.

제59차 대한소아과학회 추계학술대회 구연발표

이해관계 선언

홍길동, 김진규, 김승호, 김희갑 (저자 전부)은 본 발표 내용에
서 다음과 같은 이해관계의 내용이 있음을 밝힙니다. (사람이나
기관의 재정적 관계, 사적인 관계, 연구경쟁 관계, 지적 관심사
에서 특별히 선언해야 할 내용을 구체적으로 기술한다)

Disclosure Statements

Hong GD, Kim JK, Kim SH, and Kim HK have no
relevant financial relationships to disclose or conflicts
of interest to resolve.

예 2: 의학잡지

Paul Rutgeerts P, Severine Vermeire S, Gert Van Assche GV: [Biological Therapies for Inflammatory Bowel Diseases](#). Gastroenterology 2009;136: 1182-1197

Conflicts of interest

The authors disclose no conflicts.

Funding

Professor Rutgeerts consults, has received research support, and has lectured for Centocor, Schering Plough, Union Chimique Belge Brussels Belgium, and Abbott; and consulted for Elan-Biogen, PDL, Avidia, Bristol Myers Squibb, Millenium Pharmaceuticals, Genetech, Novimmune, and Cheocentrix. Dr Van Assche has received research support from Abbott; honoraria or speaking fees from UCB, Schering-Plough, and Abbott; and consulted for Novartis, Centocor, and Schering-Plough. Dr Vermeire has received research support from UCB (Chair); and honoraria/speaking fees from UCB, Abbott, and Schering-Plough.

Douglas K.R: [Narrow-Band Imaging Without Optical Magnification for Histologic Analysis of Colorectal Polyps](#) Gastroenterology 2009;136: 1174-1181

Conflicts of interest

The author discloses the following: Dr Rex received research support and is a member of the speakers bureau for Olympus America Corporation.

Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009

Nayer Khazeni, MD, MS; David W. Hutton, MS; Alan M. Garber, MD, PhD; Nathaniel Hupert, MD, MPH; and Douglas K. Owens, MD, MS

Background: Decisions on the timing and extent of vaccination against pandemic (H1N1) 2009 virus are complex.

Objective: To estimate the effectiveness and cost-effectiveness of pandemic influenza (H1N1) vaccination under different scenarios in October or November 2009.

Design: Compartmental epidemic model in conjunction with a Markov model of disease progression.

Data Sources: Literature and expert opinion.

Target Population: Residents of a major U.S. metropolitan city with a population of 8.3 million.

Time Horizon: Lifetime.

Perspective: Societal.

Interventions: Vaccination in mid-October or mid-November 2009.

Outcome Measures: Infections and deaths averted, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness.

Results of Base-Case Analysis: Assuming each primary infection causes 1.5 secondary infections, vaccinating 40% of the population in October or November would be cost-saving. Vaccination in October would avert 2051 deaths, gain 69 679 QALYs, and save \$469 million compared with no vaccination; vaccination in Novem-

ber would avert 1468 deaths, gain 49 422 QALYs, and save \$302 million.

Results of Sensitivity Analysis: Vaccination is even more cost-saving if longer incubation periods, lower rates of infectiousness, or increased implementation of nonpharmaceutical interventions delay time to the peak of the pandemic. Vaccination saves fewer lives and is less cost-effective if the epidemic peaks earlier than mid-October.

Limitations: The model assumed homogenous mixing of case-patients and contacts; heterogeneous mixing would result in faster initial spread, followed by slower spread. Additional costs and savings not included in the model would make vaccination more cost-saving.

Conclusion: Earlier vaccination against pandemic (H1N1) 2009 prevents more deaths and is more cost-saving. Complete population coverage is not necessary to reduce the viral reproductive rate sufficiently to help shorten the pandemic.

Primary Funding Source: Agency for Healthcare Research and Quality and National Institute on Drug Abuse.

Ann Intern Med. 2009;151:829-839.

For author affiliations, see end of text.

This article was published at www.annals.org on 6 October 2009.

www.annals.org

Author Contributions: Conception and design: A.O. Berg, M.A. Baird, J.R. Botkin, P.A. Fishman, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, S.R. Schimmel.

Analysis and interpretation of the data: A.O. Berg, J.R. Botkin, D.A. Driscoll, P.A. Fishman, R.A. Hiatt, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, J.J. Mulvihill, T.I. Pollin, S.R. Schimmel, W.M. Vollmer, J.K. Williams.

Drafting of the article: A.O. Berg, M.A. Baird, J.R. Botkin, D.A. Driscoll, P.A. Fishman, P.D. Guarino, R.A. Hiatt, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, J.J. Mulvihill, T.I. Pollin, S.R. Schimmel, W.M. Vollmer, J.K. Williams.

Critical revision of the article for important intellectual content: A.O. Berg, M.A. Baird, J.R. Botkin, D.A. Driscoll, P.D. Guarino, R.A. Hiatt, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, J.J. Mulvihill, T.I. Pollin, S.R. Schimmel, W.M. Vollmer, J.K. Williams.

Final approval of the article: A.O. Berg, M.A. Baird, J.R. Botkin, D.A. Driscoll, P.A. Fishman, P.D. Guarino, R.A. Hiatt, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, J.J. Mulvihill, T.I. Pollin, S.R. Schimmel, W.M. Vollmer, J.K. Williams.

Statistical expertise: P.D. Guarino, T.M. Morgan, S.R. Schimmel.

Administrative, technical, or logistic support: A.O. Berg, T.M. Morgan, S.R. Schimmel.

Collection and assembly of data: A.O. Berg, P.A. Fishman, G.P. Jarvik, S. Millon-Underwood, T.M. Morgan, S.R. Schimmel.

Disclaimer: The opinions expressed herein do not necessarily reflect the opinions of the Agency for Healthcare Research and Quality.

Acknowledgment: The authors thank Supriya Janakiraman, Agency for Healthcare Research and Quality Task Officer; Gurbaneet Randhawa; members of the Technical Expert Panel; Alfred Berg, Panel Chair; Wylie Burke; Lisa Madlensky; and Louise Acheson, who were instrumental in defining the parameters of this review. They also thank Lynda Booker, Mary Gauld, Homa Keshavanz, Jinhui Ma, Maureen Rice, Laura Cross-Bardell, and Silvia Visentin for their work in preparing the report and assistance with this manuscript.

Grant Support: By the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (contract 290-02-0020).

Potential Conflicts of Interest: *Honoraria:* B.J. Wilson (McMaster Evidence-based Practice Center), N. Qureshi (McMaster Evidence-based Practice Center), J. Little (McMaster Evidence-based Practice Center), J.C. Carroll (McMaster Evidence-based Practice Center), J. Allanson (McMaster Evidence-based Practice Center).

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Acknowledgment: The authors thank the reviewers for their extremely thorough and helpful reviews and suggestions.

Grant Support: By the Agency for Healthcare Research and Quality (1 F32 HS018003-01A1; Dr. Khazeni), the National Institute on Drug Abuse (2 R01 DA15612-016; Dr. Owens), a Stanford Graduate Fellowship (Mr. Hutton), and the Department of Veterans Affairs (Drs. Owens and Garber).

Potential Conflicts of Interest: None disclosed.

Reproducible Research Statement: An annotated version of the model is available in Appendix 1 (available at www.annals.org) so that others can test the authors' findings and conclusions.

Requests for Single Reprints: Nayer Khazeni, MD, MS, Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, 300 Pasteur Drive, H3143, Stanford, CA 94305.

Potential Conflicts of Interest: *Consultancies:* J.J. Mulvihill (Intergenetics). *Stock ownership or options (other than mutual funds):* J.J. Mulvihill (Intergenetics). *Grants received:* J.J. Mulvihill (U.S. Department of Health and Human Services Health Resources and Services Administration). *Grants pending:* J.J. Mulvihill (American College of Medical Genetics).

Potential Conflicts of Interest: *Consultancies:* F.K.L. Chan (Pfizer, Otsuka). *Honoraria:* F.K.L. Chan (Pfizer, Takeda, AstraZeneca). *Grants pending:* F.K.L. Chan (Takeda). *Patents pending:* J.J.Y. Sung (Nycomed). *Others:* F.K.L. Chan (chairman of the steering committee for Condor).

Potential Conflicts of Interest: *Grants received:* H.C. Yeh (NIDDK), B.B. Duncan (Brazilian National Research Council), N.Y. Wang (NIDDK, National Center for Research Resources), F.L. Brancati (NIDDK).

Potential Conflicts of Interest: *Employment:* S.M. Teutsch (Merck & Co.). *Honoraria:* L.M. Kern (Lifetime Healthcare). *Stock ownership or options (other than mutual funds):* S.M. Teutsch (Merck & Co.).

Potential Conflicts of Interest: To assure the integrity of the ACIP, the U.S. Department of Health and Human Services has taken steps to assure that there is technical compliance with ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed, or avoided altogether, through both pre-and postappointment considerations. Individuals with particular vaccine-related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest, and if any are found, they are asked to divest or forgo certain vaccine-related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare his or her conflicts.

Members with conflicts are not permitted to vote if the conflict involves the vaccine or biologic being voted upon. Members of the ACIP have disclosed the following: *Grants received:* J. Englund (MedImmune, Sanofi Pasteur, Novartis); W.A. Keitel (Novartis). *Payments made to Tufts Medical Center for participation in clinical trials:* C.H. Meissner (MedImmune, Wyeth).

Corresponding Author: Carol Friedman, DO, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Mailstop E52, Atlanta, GA 30333; e-mail, caf7@cdc.gov.

Potential Conflicts of Interest: *Board memberships:* S.A. Flanders (Society of Hospital Medicine [serves as president]) *Employment:* S.A. Flanders (University of Michigan). *Consultancies:* J.B. Froehlich (Pfizer, Sanofi-Aventis). *Honoraria:* J.B. Froehlich (Sanofi-Aventis, Pfizer, Merck/Schering-Plough). *Expert testimony:* J.B. Froehlich (testified for the defense in case of malpractice regarding vascular disease diagnosis). *Grants received:* J.B. Froehlich (Mardigian Foundation, Blue Cross Blue Shield of Michigan, The Fibromuscular Dysplasia Society of America, W.L. Gore & Associates). *Grants pending:* J.B. Froehlich (Sanofi-

예 3: 교과서, 서적

- Chapter별 저자들:

Potential conflict of interest 기재

이해관계 (conflict of interest)

논문의 출판과 관련된 사람(저자, 편집인, 전문가심사자, 출판인 등) 또는 기관이 특정 논문에 재정적인 이익이 걸려 있거나 사적인 특별한 관련이 있는 경우를 말한다. 이러한 이해관계는 과학성을 생명으로 하는 학술논문의 출판과 관련된 판단에 자칫 왜곡을 유발할 수 있는 가능성이 있기 때문에 특히 경계의 대상이 된다. 어떠한 이해관계에 의한 영향도 학술관련 판단에서 모두 배제되어야 한다

이해관계 형성 여건

- 정도가 미미한 수준부터 매우 심각한 단계까지 **넓은 범주에** 걸쳐 있으며, 저자나 출판 관련자가 어떠한 이해관계가 있어서 실제로 어떻게 영향을 받았는가 여부보다 어떠한 **이해관계에 연루되었다는 사실 자체가 중요**

이해관계의 유형 (ICMJE)

- 사람이나 기관의 재정적인 관계
- 사적인 관계(겸직, 학문적인 경쟁, 지적소유권 경쟁 등)
- 연구의 경쟁
- 지적인 관심사

- 재정적인 관계(financial relationship)

가장 흔하고 또 발견하기가 비교적 쉬운 유형이다. 저자 또는 저자 소속 기관이 특정 기관, 회사, 단체 등으로부터 지속적으로 재정적인 지원을 받거나 직접 연구구비를 지원받아 수행한 연구결과물을 출판하는 경우가 해당된다. 그 외에도 고용, 자문, 주식보유, 강연료나 자문료, 유료 증언 등의 경우도 재정적인 관계에 의한 영향을 줄 수 있다. 물론 편집인, 전문가심사자, 출판인 등도 재정적인 관계가 있어 출판 여부의 판단에 영향을 줄 수 있기 때문에, 이러한 관계가 있으면 반드시 공개할 의무가 있다

- 사적인 관계(personal relationship)

재정적인 관계 외에 저자나 전문가 심사자가 사적인 관계를 갖는 경우이다. ICMJE는 그 예로 겸직(dual commitments), 이익 경쟁(competing interests) 또는 지적재산권 경쟁(competing loyalties)을 열거하고 있다.

- 연구 경쟁(academic competition)

이는 특히 경쟁관계에 있는 연구자들이 저자와 전문가심사자의 관계로 마주하게 되는 경우에 그러하다. 이는 특히 전문가심사(peer review)에서 필요한 윤리वाद도 직결된다.

- 지적인 관심사(intellectual passion)

특히 편집인이나 심사자가 개인적인 관심사나 취향에 의하여 판단함으로써 공정성을 잃을 수도 있다. 이러한 경우에 해당하면 과학적인 판단에 관여하지 않는 것이 가장 좋은 방법이다.

이해관계의 대상자

저자, 편집인, 전문가심사자, 출판인 등 논문 출판과 관련된 모든 과정의 사람이나 그들의 소속 기관이 여기에 해당한다. 저자는 심각한 과학적 사기와 같은 출판윤리의 위배가 아니더라도 얻는 결과의 정리와 분석에서 이해관계에 의하여 특정 제품이나 회사에 유리하도록 논문을 작성할 수 있다. 전문가심사자의 경우 대부분이 해당 학술지의 저자이고 또 독자이기 때문에 학술지에 끼치는 영향이 크다. 논문의 출판 과정에서 저자와 대립하거나 또는 유착하여 객관적인 판단을 하는 데에 영향을 줄 수 있다. 또한 저자의 이익을 가로챌 수도 있다.

이해관계의 대책과 예방

- ICMJE가 2008년도에 개정한 통일양식은 모든 논문출판 관련자들이 **이해관계를 고지하도록 각 학술지에 지침으로 제시하고 있다.** 즉, 이해관계가 있다는 사실보다 이를 숨기는 것을 실제 문제로 삼는다는 의미이다. 대부분의 학술지가 이러한 **이해관계의 가능성이 있는 모든 사실을 있으면 통보하고, 없으면 없다고 선언하기를 요구하고 있다.** 편집인이나 전문가심사자 중의 누구라도 만약 이해관계에 연루된 논문이 있는 경우, 가급적 어떠한 판정에 관여하지 않는 것이 바람직하다.

ICMJE

www.icmje.org

- [Uniform Format for Disclosure of Competing Interests in ICMJE Journals](#) (Oct. 09, 2009)
- [ICMJE Uniform Disclosure Form for Potential Conflicts of Interest](#) (Oct. 09, 2009)
- [Sample ICMJE Uniform Disclosure Form for Potential Conflicts of Interest](#) (Oct. 09, 2009)

The screenshot shows the ICMJE website homepage. At the top, there is a navigation bar with the ICMJE logo and the text 'INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS'. Below this is a search bar and a 'GO' button. The main content area is divided into several sections. On the left, there are links for 'About ICMJE', 'Uniform Requirements for Manuscripts (URM)', 'Journals Following URM', 'Updates & Editorials', 'Archives', and 'External Links'. The central section is titled 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publications' and contains three columns of links: 'Statement of Purpose', 'Publishing & Editorial Issues', and 'Manuscript Preparation'. Below this is a section for 'ICMJE Member Publications & Organizations' featuring four journal covers: 'Annals of Internal Medicine', 'British Medical Journal', 'Canadian Medical Association Journal', and 'Croatian Medical Journal'. On the right side, there is a large orange banner for 'INSIDE the UNIFORM REQUIREMENTS for MANUSCRIPTS'. Below the banner is a 'Recent Announcements, Updates & Editorials' section, which is circled in red. This section contains links to 'Uniform Format for Disclosure of Competing Interests in ICMJE Journals (10/09) (PDF)', 'ICMJE Uniform Disclosure Form for Potential Conflicts of Interest (10/09) (PDF)', 'Sample ICMJE Uniform Disclosure Form for Potential Conflicts of Interest (10/09) (PDF)', and 'All Announcements, Updates & Editorials (Articles)'. Below this is a 'Frequently Asked Questions at a Glance' section with a question about clinical trial results posted at ClinicalTrials.gov.

Uniform Format for Disclosure of Competing Interests in ICMJE Journals

- Disclosure of financial associations of authors of articles published in biomedical journals has become common practice. The information provided in these disclosures helps the reader to understand the relationships between the authors and various commercial entities that may have an interest in the information reported in the published article. At present, many journals ask authors to report such relationships by completing a form with information about their financial associations. The journals then either post the complete information online or create a summary of the information and publish it with the article in question. Although efforts are under way to establish uniform reporting systems, there is currently no uniform vehicle for the disclosure of financial associations. Thus authors may provide similar information to different journals in multiple formats. In addition, slight differences among journals in requirements for reporting can lead to confusion, as the same individual may report different information to different journals. With this editorial, which is being published simultaneously in all International Committee of Medical Journal Editors (ICMJE) journals, we introduce a new disclosure form that has been adopted by all journals that are members of the ICMJE. We encourage other journals to adopt this reporting format, and we are placing the form in the public domain.
- We ask authors to disclose four types of information. First, their associations with commercial entities that provided support for the work reported in the submitted manuscript (the time frame for disclosure in this section of the form is the life span of the work being reported). Second, their associations with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript (the time frame for disclosure in this section is the 36 months before submission of the manuscript). Third, any similar financial associations involving their spouse or their children under 18 years of age. Fourth, nonfinancial associations that may be relevant to the submitted manuscript.

The form now posted on the ICMJE Web site (www.icmje.org/coi_disclosure.pdf) includes instructions to help authors provide the information, and a sample completed form is also available (www.icmje.org/sample_disclosure.pdf). Authors can download the form from the Internet, add the requested information, and save the completed form on their computer. The completed form can then be uploaded to the Web site of the journal that has requested the information. Since all ICMJE journals now use the same reporting format, authors may save a partially completed form on their computers; when a manuscript is ready for submission to a journal that accepts this reporting format, authors can simply finish completing the form by adding information specific to the manuscript and then upload the completed form to the journal's Web site. Our goal is to make the process of disclosure uniform and easy; the new form should eliminate the need to reformat disclosure information for specific journals.

We realize this disclosure form requires authors to report a great deal of information about their relationships with entities that could be viewed as having interests that compete with the research being reported. With this in mind, some journals may ask for all these details at the time of initial manuscript submission, whereas other journals may ask for much less information at submission and require completion of the detailed form later in the editorial process. These decisions will be left to the discretion of the journal.

We also realize that to be useful, the reporting format must be responsive to community needs. Although ICMJE member journals have "use tested" the form, there may be situations that are not covered by the form, aspects of the instructions that are unclear, or bugs in the programming that we have not yet discovered. Therefore we regard the period from publication of this editorial until April 10, 2010, as a period of beta testing. We encourage you to let us know about problems that arise with the form and to send us your comments by using the comments feature at the home page of the ICMJE Web site (www.icmje.org). The ICMJE will meet in late April 2010 and will adapt the form to address concerns identified by users. In the future we will revisit the form's usefulness and modify it as needed. We are grateful to the authors who take the time to provide complete disclosure information and thus help to ensure the transparency of the publication process. By adopting a uniform format, we hope to make the process of disclosure of competing interests easier for authors and less confusing for readers.

- Jeffrey M. Drazen, M.D.
Editor-in-Chief, New England Journal of Medicine
- Martin B. Van Der Weyden, M.D.
Editor, The Medical Journal of Australia
- Peush Sahni, M.S., Ph.D.
Representative and Past President, World Association of Medical Editors
- Jacob Rosenberg, M.D., D.Sc.
Editor, Journal of the Danish Medical Association
- Ana Marusic, M.D., Ph.D.
Editor-in-Chief, Croatian Medical Journal
- Christine Laine, M.D., M.P.H.
Editor, Annals of Internal Medicine
- Sheldon Kotzin, M.L.S.
Associate Director for Library Operations, National Library of Medicine
- Richard Horton, F.Med.Sci.
Editor, The Lancet
- Paul C. Hébert, M.D., M.H.Sc.
Editor-in-Chief, Canadian Medical Association Journal
- Charlotte Haug, M.D., Ph.D., M.Sc.
Editor-in-Chief, Norwegian Medical Journal
- Fiona Godlee, M.B., B.Chir., B.Sc.
Editor-in-Chief, BMJ
- Frank A. Frizelle, M.B., Ch.B.
Editor-in-Chief, The New Zealand Medical Journal
- Peter W. de Leeuw, M.D., Ph.D.
Editor-in-Chief, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)
- Catherine D. DeAngelis, M.D., M.P.H.
Editor-in-Chief, JAMA

각 잡지의 선언의 예:

Uniform Format for
Disclosure of
Competing Interests
in ICMJE Journals
New Engl J Med
2009;361:1896-7
(Nov. 5, 2009)

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

INSTRUCTIONS:

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form has five parts.

1. Identifying information.

Each author should submit a separate form. Provide complete information and double-check the manuscript number. If you are NOT the corresponding author please insert his or her name.

2. The work under consideration for publication.

Please provide information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The idea is to provide for the reader information about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. If you check the "No" box it means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds to pay you. If you or your institution did receive funds from a third party to support the work, check "Yes" along with the appropriate boxes to indicate the type of support and whether you or your institution received it.

3. Relevant financial activities outside the submitted work.

Please report all sources of revenue relevant to the submitted work that accrued either directly to you or were paid to your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. If there is any question, it is usually better to disclose a relationship than not to do so. Please note that your interactions with the work's sponsor outside the submitted work should be listed here. For each category list each entity on a separate line. Use as many lines as necessary to provide complete information. In addition, please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

The goal of this section is to provide information for our reviewers and readers about your interactions with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to benefit financially from the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as the NIH or the MRC, need not be disclosed. For example, if the NIH sponsored a piece of work you have been involved in but drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Financial relationships involving your spouse or partner or your children (under 18 years of age).

If monies from the types of relationships listed in Section 3 were paid to your spouse or partner or dependent children, please list the type of activity and source of the money.

5. Non financial associations.

Please report any personal, professional, political, institutional, religious, or other associations that a reasonable reader would want to know about in relation to the submitted work.

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

Section 1. Identifying Information

Given Name: Surname: Effective Date:
 (or first) (or last) Format example: 07-August-2008

Are you the corresponding author? Yes No

Corresponding author's name:

Manuscript Title:

Manuscript Identifying Number (if you know it):

Section 2. Information about the support of the work under consideration for publication

Did you or your institution at any time receive payment or support in kind for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

- No
 Yes, specify nature of compensation

Section 3. Information about relevant financial relationships outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with any entities that have an interest related to the submitted work. Use one line for each entity; add as many lines as you need. Use the comments column to indicate any additional information that you think a reader or editor would want to know about the compensation. Report relationships that were present during the 36 months prior to submission. In addition please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

If you have more than one relationship, click "Add +" to add a row. Click "Del x" to delete an extra row.

Type of Relationships (in alphabetical order)	No	Money Paid to You	Money to Your institution	Entity	Comments	
Board membership	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Lily Pads Unlimited	Serve on Steering Committee for grants given to people at our medical school underwritten by Lily Pads Unlimited.	Del x
						Add +
Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Croak Inc.	Ad hoc advisor	Del x
						Add +

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

Employment	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Lily Pads Unlimited	A fraction of my total compensation-paid though Frog University-derives from my working for Lily Pads in their on-site laboratory	Del ×
Add +						
Expert testimony	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Frogs versus Snakes	Served as an expert witness against Severus Snake in a premature death lawsuit. Paid by defendant's lawyers	Del ×
Add +						
Gifts	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Faculty of Medicine at Pigsty University	Received a week's free use of a condo in Aspen Colorado during ski season for myself and family in payment for serving as a spokesperson for their new anti-slime campaign	Del ×
Add +						
Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Gunko-Smithkan	Investigator in study of an insect digestive aid	Del ×
Add +						
Honoraria	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Rivet Inc.	Received fees for speaking groups of other frogs about Rivet's products.	Del ×
Add +						
Payment for manuscript preparation	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			Del ×
Add +						
Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US Patent 11223344	Patent on a method to entice beautiful women to kiss the holder of a special charm-No licensee yet and no money received.	Del ×
Add +						
Royalties	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	US Patent 11223345	Receive royalty payments from Micky amounting to 10% of gross sales with this split between my institution and me 75%-25%. Patent expires in 2015.	Del ×
Add +						

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

Payment for development of educational presentations including service on speakers' bureaus	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Rivet Inc.	Rivet and Frog University co-develop educational products for the general public. These products are aimed at young women and help them distinguish toads from true princes disguised as frogs. Rivet sells such products.	Del x
						Add +
Stock/stock options	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Tadpole Inc.	I own options on 10,000 shares of Tadpole stock, currently valued at \$0.01 each. Stock is privately held and not publicly traded.	Del x
						Add +
Travel/accommodations expenses covered or reimbursed	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Sunlight Stop Inc.	Travel grants to the two major frog meetings a year (one in US and one in Europe) for the past 5 years. Business class air travel, meals and a 5 star hotel.	Del x
						Add +
Other (err on the side of full disclosure)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Frog Nation	My institution receives payments of \$1000 each time Frog Nation uses my picture in any public format.	Del x
						Add +

Section 4. Information about financial relationships involving your spouse or partner or your children (under 18 years of age).

Do your children or your spouse or partner have financial relationships with entities that have an interest in the content of the submitted work?

- No other relationships/conditions/circumstances that present potential conflict of interest
- Yes, the following relationships/conditions/circumstances are present (explain below):

Section 5. Information about relevant nonfinancial associations.

Do you have any relevant nonfinancial associations or interests (personal, professional, political, institutional, religious, or other) that a reasonable reader would want to know about in relation to the submitted work?

- No relevant nonfinancial relationships/conditions/circumstances to report.
- Yes, the following relevant nonfinancial relationships/conditions/circumstances are present: (explain below)



ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Save Form